debt_leverage_profile
Near-zero debt; cash-funded clinical-stage biotech with ~$200M+ cash runway; 20% rate rise has negligible P&L impact
Inferred
Agent_Inference
interest_rate_sensitivity
Minimal; no material floating-rate debt; higher rates modestly reduce cash yield on treasury holdings but immaterial to operations
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) Chinese API synthesis chokepoint for precursor chemistry; 2) Single-source CRO/CDMO concentration in EU/North America
Inferred
Agent_Inference
international_expansion_readiness
No international revenue; clinical-stage US-focused company; sovereign currency devaluation exposure is effectively zero
Inferred
Agent_Inference
geographic_footprint
Entirely US-based revenue and operations; no material foreign currency exposure in top markets
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High; single CDMO likely manufactures palazestrant drug substance, representing non-substitutable critical path supplier
Inferred
Agent_Inference
business_model_type_primary
Clinical-stage biotech; no commercial product; cloud disruption would impair R&D data systems but not revenue directly
Inferred
Agent_Inference
business_model_type_secondary
IP licensing and future royalty/milestone model upon partnership or commercial approval; no current secondary revenue stream
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; uses standard SaaS/cloud tools for R&D operations; no proprietary platform lock-in externally
Inferred
Agent_Inference
howey_test_risk_index
Not applicable; revenue model is drug development/licensing, not an investment contract; Howey Test risk is negligible
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Low-moderate; handles clinical trial patient data subject to HIPAA, GDPR (EU trials); CCPA exposure limited given no consumer sales
Inferred
Agent_Inference
antitrust_exposure_flag
Very low; single-asset clinical-stage company with no market share; no pricing power or competitive dominance to scrutinize
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
0% recurring commercial revenue; 100% transactional/milestone-driven; currently pre-revenue relying on equity financing
Inferred
Agent_Inference
monetization_vector
Future monetization via drug approval royalties, licensing milestones, or acquisition premium; no current commercial monetization
Inferred
Agent_Inference
pricing_architecture
No commercial pricing yet; future oncology drug pricing likely $100K–$200K+ annually per patient, subject to payer negotiation
Inferred
Agent_Inference
pricing_power_rating
Moderate-high potential; targeted oncology therapy with biomarker selection could command premium pricing if differentiated efficacy proven
Inferred
Agent_Inference
target_gross_margin_bracket
Pharmaceutical gross margins typically 70–85% post-commercialization; pre-revenue currently so margin is negative
Inferred
Agent_Inference
churn_vulnerability_index
Not applicable; no subscription or recurring customer base; no free-rider leakage problem in current business model
Inferred
Agent_Inference
headcount_cost_structure
Headcount-sublinear at scale; clinical/regulatory headcount grows modestly; commercial launch would require step-change hiring
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth is capital-intensive in trials but sublinear post-approval; manufacturing scales without proportional headcount
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise network; direct R&D operations model with no franchisee compliance risk
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale (post-commercial), CAC via oncologist detailing ~$5K–$15K per prescriber; LTV very high given chronic treatment
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; drug efficacy is independent of user base size; no platform or data network dynamic
Inferred
Agent_Inference
asset_efficiency_ratio
-30.5% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate-high; oncology treatments are non-discretionary; however, clinical-stage funding is vulnerable to risk-off capital markets
Inferred
Agent_Inference
customer_segment_primary
Future: breast cancer patients with ESR1 mutations and oncology prescribers; currently no paying customers
Inferred
Agent_Inference
customer_segment_secondary
Potential pharma/biotech licensing partners seeking oral SERD assets; no secondary commercial customer segment currently
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated to clinical trials (Phase 3 OPERA trial); no legacy infrastructure reallocation; forward-looking R&D spend dominant
Inferred
Agent_Inference
sec_cik
0001750284
High
SEC-EDGAR
ticker
OLMA
High
SEC-EDGAR